Clinical Scorecard: Exploring the Vaginal Microbiome's Role in Cancer Development

At a Glance

Key Highlights

• Healthy vaginal microbiomes are typically Lactobacillus-dominant with low species diversity, providing protection against dysbiosis.
• Non-Lactobacillus–dominant microbiomes, including Atopobiaceae species, are associated with HPV persistence and cervical cancer progression.
• Probiotic interventions show mixed results in establishing protective Lactobacillus species and preventing bacterial vaginosis recurrence.

Guideline-Based Recommendations

Diagnosis

• Use traditional methods such as vaginal pH, whiff test, microscopy, and Amsel criteria or Nugent score for bacterial vaginosis diagnosis.
• Consider nucleic acid amplification tests to identify BV-associated bacteria like Gardnerella vaginalis and Fannyhessea vaginae.

Management

• Antibiotic treatment for bacterial vaginosis can induce short-term microbiome changes but often does not prevent recurrence.
• Probiotic use (e.g., Lactobacillus crispatus CTV-05) after antibiotics may modestly reduce BV recurrence but requires further study for sustained colonization.

Monitoring & Follow-up

• Monitor for recurrence of bacterial vaginosis within 12 months post-treatment.
• Assess cervicovaginal microbiome composition in women with HPV infection or cervical lesions to evaluate cancer risk.

Risks

• Bacterial vaginosis increases risk for adverse pregnancy outcomes and acquisition of sexually transmitted infections including HPV.
• Non-Lactobacillus–dominant microbiomes may promote chronic inflammation and immune dysregulation contributing to carcinogenesis.

Patient & Prescribing Data

Women with bacterial vaginosis and HPV-related cervical lesions

Antibiotics provide short-term microbiome shifts; probiotics show variable efficacy in restoring Lactobacillus dominance and preventing recurrence.

Clinical Best Practices

• Maintain awareness of vaginal microbiome composition as a factor in HPV persistence and cervical cancer risk.
• Utilize both traditional and molecular diagnostic tools for accurate identification of bacterial vaginosis.
• Consider personalized approaches to microbiome modulation accounting for patient-specific factors such as ethnicity, sexual behavior, and diet.
• Recognize the potential role of probiotics as adjuncts in managing vaginal dysbiosis but interpret efficacy data cautiously.
• Support ongoing research into microbiome-targeted therapies for cancer prevention and treatment.

References

• Jimenez et al, The Journal of Infectious Diseases
• Amsel criteria and Nugent score for BV diagnosis
• Probiotic intervention study with Lactobacillus crispatus CTV-05